A Phase 1/2 interventional study of ICP-490 and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-09.
Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 448 studies in Multiple Myeloma with a site in China — 238 open to participants now, 275 under way, 47 of them phase 3. Multiple Myeloma · China.
Among the 448 studies in Multiple Myeloma with a site in China, this one is the 131st largest by planned enrollment of the 406 interventional ones that give a count, is one of 60 that started in 2023, is one of 65 in phase 1/2, reaches primary completion later than 43 of the 274 other live ones, and was the 226th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 768 are open to participants now.
Browse Multiple Myeloma studies →238 of the 448 studies in Multiple Myeloma with a site in China are open now. Recruiting first, the newest first:
Beijing Chao Yang Hospital · Sites in China
Ages 18+
AstraZeneca · Sites in China, United States, Australia and 15 more countries
Ages 18–130
Mabwell (Shanghai) Bioscience Co., Ltd. · Sites in China
Ages 18+
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18–80
Chinese PLA General Hospital · Sites in China
Ages 18–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 584 Multiple Myeloma studies recruiting now, 429 (73%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
448 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 216 · Phase 2 130 · Phase 3 71 · Phase 4 16
First in 2008; this study’s year is marked. 60 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 40 across the 406 interventional studies, 210 across the 41 observational. Of the 58 that completed or were terminated, 18 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
187 of 448 have an industry lead sponsor. The 10 most frequent:
This study is registered under Beijing InnoCare Pharma Tech Co., Ltd., one of the names counted as InnoCare Pharma Limited. Under that name alone:
Beijing InnoCare Pharma Tech Co., Ltd. is the lead sponsor of 61 studies on the registry; 37 are open to participants now.
InnoCare Pharma Limited has 1 study filed under Multiple Myeloma — fewer than ten, so there is no comparison to draw.
74 of the studies in Multiple Myeloma with a site in China that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06520176Phase 3The Affiliated People's Hospital of Ningbo UniversityComparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients | 2026-12 |
| NCT05519085Phase 3CelgeneA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | 2027-01-10 |
| NCT06508983Phase 3Hangzhou Sumgen Biotech Co., Ltd.A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients | 2027-03-31 |
| NCT03319667Phase 3SanofiA Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | 2027-04-05 |
| NCT06895512Phase 3Shanghai Henlius BiotechA Study to Evaluate the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma | 2027-07 |
Add all 74 to your calendar (.ics) → With an account.
Among the 448 studies in Multiple Myeloma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, non-randomized and open-label phase I/IIa clinical study to evaluate the safety, tolerability, and efficacy of ICP-490 in patients with relapsed and/or refractory multiple myeloma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female patients of should have a negative blood pregnancy test result within 48 h prior to the first dose of drug.
Exclusion Criteria:
Patients who have received systemic treatment with or other drugs within 14 days prior to the first dose of investigational drug.
Subjects are allowed to use topical, ocular, intra-articular, intranasal, and inhaledcorticosteroid ; short-term use (≤ 7 days) of corticosteroid for prophylaxis (e.g., contrast agent allergy) or for the treatment of non- diseases (e.g., delayed reaction caused by contact allergens) is permitted.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ICP-490
Drug: ICP-490 · Drug: Dexamethasone
Several dose groups of ICP-490 are planned for the dose exploration.
Oral Dexamethasone is administered on Days 1, 8, 15, and 22 of each 28-day cycle.
Phase I : Incidence, type, and severity of adverse events (AEs) as judged according to NCI-CTCAE V5.0
AE refers to any adverse event occurring in subjects during clinical research period. The incidence and type of AEs will be evaluated and the severity will be judged according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version5.0.
Time frame: Through study completion, an average of 3 years
Phase I : Incidence, type, and severity of dose-limiting toxicities (DLTs)
The dose-limiting toxicity (DLT) assessed in the phase I dose exploration study is defined as AEs related to study treatment that meet the following criteria (according to the NCI CTCAE v5.0 criteria) and occur in Cycle 1.
Time frame: Through study completion, an average of 3 years
Phase I : RP2Ds and/or MTDs
Phase I is the dose exploration study of ICP-490 to preliminarily determine RP2Ds (probably more than one) and MTD (if applicable). MTD: The dose level corresponding to the dose group whose posterior probability of DLT incidence estimated by PAVA (pool adjacent violators algorithm) is closest to the target toxicity probability (25%).
Time frame: Through study completion, an average of 3 years
Phase II : ORR (defined as sCR + CR + VGPR + PR) assessed according to IMWG criteria.
Disease response will be assessed according to the 2016 IMWG response criteria.
Time frame: Through study completion, an average of 3 years
Maximum concentration (Cmax)
Maximum concentration (Cmax) will be calculated through multiple plasma concentrations drawn from the patients after administration.
Time frame: Through study completion, an average of 3 years
Time to maximum concentration (Tmax)
Time to maximum concentration (Tmax) will be calculated through multiple plasma concentrations drawn from the patients after administration.
Time frame: Through study completion, an average of 3 years
Half-life (T1/2)
Half-life (T1/2) will be calculated through multiple plasma concentrations drawn from the patients after administration.
Time frame: Through study completion, an average of 3 years
Area under the concentration-time curve (AUC0-∞ and AUC0-t)
Area under the concentration-time curve (AUC0-∞ and AUC0-t) will be calculated through multiple plasma concentrations drawn from the patients after administration.
Time frame: Through study completion, an average of 3 years
Apparent clearance (CL/F)
Apparent clearance (CL/F) will be calculated through multiple plasma concentrations drawn from the patients after administration.
Time frame: Through study completion, an average of 3 years
Apparent volume of distribution during terminal phase (Vz/F)
Apparent volume of distribution during terminal phase (Vz/F) will be calculated through multiple plasma concentrations drawn from the patients after administration.
Time frame: Through study completion, an average of 3 years
Steady-state PK parameters
Steady-state PK parameters will be calculated through multiple plasma concentrations drawn from the patients after administration.
Time frame: Through study completion, an average of 3 years
The overall response rate (ORR) assessed according to the International Myeloma Working Group (IMWG) criteria (ORR, defined as stringent complete response (sCR) + complete response (CR) + very good partial response (VGPR) + partial response (PR))
Disease response will be assessed according to the 2016 IMWG response criteria.
Time frame: Through study completion, an average of 3 years
Phase I & IIa : Complete response rate (CRR, defined as sCR + CR) assessed according to IMWG criteria
Disease response will be assessed according to the 2016 IMWG response criteria.
Time frame: Through study completion, an average of 3 years
Phase I & IIa : Very good or better partial response rate assessed according to IMWG criteria (≥ VGPR rate, defined as VGPR + sCR + CR)
Disease response will be assessed according to the 2016 IMWG response criteria.
Time frame: Through study completion, an average of 3 years
Phase I & IIa : Time to response (TTR) assessed according to IMWG criteria
Disease response will be assessed according to the 2016 IMWG response criteria
Time frame: Through study completion, an average of 3 years
Phase I & IIa : Duration of response (DOR) assessed according to IMWG criteria
Disease response will be assessed according to the 2016 IMWG response criteria
Time frame: Through study completion, an average of 3 years
Phase I & IIa : Progression-free survival (PFS) assessed according to IMWG criteria
Disease response will be assessed according to the 2016 IMWG response criteria
Time frame: Through study completion, an average of 3 years
Phase I & IIa : Overall survival (OS)
The follow-up visits should be carried out every 12 weeks after the last dose via telephone or other methods to obtain the survival status information of patients.
Time frame: Through study completion, an average of 3 years
Started Mar 2023 (actual). Primary completion is estimated for Jul 2025, 28 months after the start.
Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 28 months is below that.
Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing InnoCare Pharma Tech Co., Ltd. →